Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
Critical care
See all tags

VORTEX nozzle was included into the list of pharmaceutical benefits by Dental and Pharmaceutical Benefit Agency

On the 5th of April of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a positive decision for inclusion of VORTEX nozzle (spare part for VORTEX inhalation container) into the list of pharmaceutical benefits. Although VORTEX nozzle has shown the same level of clinical benefit in comparison to other nozzles from the product group Y93DB05 (masks, inhalation accessories), it was considered to be included in the list of pharmaceutical benefits due to lower price of 45.42 SEK per product versus comparators.

The decision will enter into its force from the 19th of April, 2018.

See full information in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Tags
Sweden
Medical devices

The latest related news

11
Dec 2024

2025 Swedish NordDRG system released

In November 2024, the annual update of the Swedish NordDRG system was published to come into force on January 1, 2025. No new DRGs were introduced. In 2025, to obtain DRG tariffs, cost-weights must be multiplied by a base rate of 88,061 SEK.
Read more
01
Nov 2024

2025 Swedish procedure coding system (KVÅ) released

In October 2024, the annual update of the Swedish procedure coding system (Classification of Health Care Measures, KVÅ) was released to come into force on January 1, 2025. A total of 55 new surgical procedure codes and 43 new medical procedure codes were introduced concerning diagnostic imaging, endoscopy, ENT, men’s health, nephrology and urology, gynecology, orthopedics, pulmonology, and some other areas.
Read more
02
Oct 2024

Hybrid closed-loop systems to be evaluated within the Orderly introduction framework in Sweden

On September 20, 2024, the Swedish Medical Technologies Product (MTP) Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of hybrid closed-loop systems for adults with type 1 diabetes. This evaluation is a part of the Orderly introduction framework, a staged process aimed at managing the national introduction of novel technologies. Based on the TLV assessment, the MTP Council will make recommendations to regions regarding the implementation of the technology and the criteria for use.
Read more